Penn Quantitative Imaging Resource for Pancreatic Cancer
Our mission is to facilitate the development of effective therapies for pancreatic ductal adenocarcinoma (PDA) via the applications of imaging tools. We strive to develop robust imaging tools in murine models of PDA and translate them to the clinic in settings of co-clinical imaging.
About The Website
We will be making updates over the course of the U24CA231858 project (9/2018-8/2023). As the project develops, we will share resources and imaging data produced in the project including but not limited to:
- Imaging tool library - Tools including MRI pulse programs and data analysis software developed.
- SOP library – standardized protocols for generations of orthotopic and xenograft models.
- Data repository – preclinical imaging data and IHC data; clinical imaging data and companion clinical information.
The publication below represents the first detailed evaluation of DCE-MRI’s utility for detecting PDA responses to stroma-directed therapy.
Cao J, Pickup S, Clendenin C, Blouw B, Choi H, Kang D, Rosen M, O'Dwyer PJ and Zhou R. Dynamic contrast-enhanced MRI detects responses to stroma-directed therapy in mouse models of pancreatic ductal adenocarcinoma. Clin Cancer Res. Dec. 2018 (Epub ahead of print).
IRB Protocol Approved by Halozyme
January 18, 2019
Halozyme Therapeutics approved the phase-2 clinical trial our team has proposed, and the company is working with us to finalize the details of the sponsorship. This phase-2 trial is entitled "Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer". The primary goal of this trial is to test the utility of DCE-MRI and DWI markers for assessing the PDA stroma, the early response to stroma-directed investigational drug, PEGPH20, which is developed by Halozyme and is currently under phase-3 clinical trial.